Law Journal Newsletters

An ALM Website

MEDICAL MALPRACTICE LAW & STRATEGY

January 2013

Drug Marketing to Doctors: Changes May Be On the Way

By Janice G. Inman

The cornerstone of many FDA enforcement actions against pharmaceuticals manufacturers in recent years has been the charge that they have "misbranded" their pharmaceutical products by promoting them for uses not approved by the FDA. Now, the Second Circuit has thrown the concept of criminal liability for misbranding by means of off-label-use promotion into turmoil.

Log In

Subscribers: Log in below to read the full story

Already subscribe but haven't registered for all the benefits of the website?

Subscribe

Click below to subscribe to
MEDICAL MALPRACTICE LAW & STRATEGY

Subscribe

Pay-Per-View

You can purchase this article for $20.00
Click below

Purchase Article

ARTICLES FROM RELATED NEWSLETTERS

BUSINESS CRIMES BULLETIN

Navigating the Minefield of U.S. Export Control

While the export control regulatory framework can present a dizzying array of requirements for exporters, companies also risk being held responsible for the activities of others, including those abroad who trans-ship their products to destinations embargoed by the United States, or in violation of U.S. licensing or regulatory requirements.

LEGAL TECH NEWSLETTER

What ERP Can Teach About ELM Adoption

Following in the footsteps of Enterprise Resource Planning (ERP), Enterprise Legal Management (ELM) holds out the potential to link risk and legal data to enable the global enterprise to proactively mitigate legal risk, streamline the legal process, and make insightful decisions in response to market or regulatory changes.